StreetAlpha.app
Home › Stocks › KVUE

Kenvue Inc. (KVUE)

Consumer Defensive
$19.31
▼ −1.28%
LAST CLOSE · OCT 30

Kenvue sells consumer health products, including pain relievers, skin care, oral care and baby care items sold worldwide. It last closed at $19.31 on Oct 30, down 1.28% on the day. The next earnings report for KVUE is expected around Tue, Feb 16, 2027, after the close. For the quarter ended Sep 2026, KVUE reported EPS of $0.22 on revenue of $3.89B, with revenue up 3.2% from a year ago. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months KVUE insiders bought $111.0M of stock on the open market and sold $747K, according to SEC Form 4 filings.

AI Auto Pilots
Is KVUE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold KVUE.

Key Stats

Last 12 months
Results
Revenue
$15.5B
+3.5% vs a year ago
Net income
$1.7B
+17.9% vs a year ago
EPS (diluted)
$0.88
+17.3% vs a year ago
Free cash flow
$2.3B
15.1% margin
Valuation
Market cap
$37.1B
1.92B shares
P/E
21.9
Price over 12 month EPS
Price to sales
2.4
Market cap over revenue
Dividend yield
5.39%
$1.04 a share over 12 months
Balance sheet
Cash & equivalents
$1.0B
At Sep 27
Shareholder equity
$10.2B
Shares outstanding
1.92B
At Oct 26
Fiscal year endsJanuary
ExchangeNYSE
Financials history
FY2022: $15.1B$15.1BFY2022FY2023: $14.9B$14.9BFY2023FY2023: $15.4B$15.4BFY2023FY2024: $15.5B$15.5BFY2024FY2025: $15.1B$15.1BFY2025

From KVUE's SEC filings, latest 10-Q for the period ending Sep 27, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.

Next report
Feb 16
Estimated date · After the close
Reported EPS
$0.22
Quarter ended Sep 2026
Year ago EPS
$0.21
+4.8% on a GAAP basis
Revenue
$3.89B
+3.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.16Dec '24Mar 2025: $0.17Mar '25Jun 2025: $0.22Jun '25Sep 2025: $0.21Sep '25Dec 2025: $0.17Dec '25Mar 2026: $0.25Mar '26Jun 2026: $0.24Jun '26Sep 2026: $0.22Sep '26Latest $0.22
Revenue by quarter
Dec 2024: $3.66BDec '24Mar 2025: $3.74BMar '25Jun 2025: $3.84BJun '25Sep 2025: $3.76BSep '25Dec 2025: $3.78BDec '25Mar 2026: $3.91BMar '26Jun 2026: $3.96BJun '26Sep 2026: $3.89BSep '26Latest $3.89B
How KVUE moved after its last 8 reports
Average move the session after a report ±3.7%
Oct 30, 2026Time not announced−1.3%
Aug 6, 2026Time not announced−2.5%
May 7, 2026Time not announced+0.2%
Feb 17, 2026After the close+2.5%
Nov 3, 2025Time not announced+12.3%
Jul 14, 2025Time not announced+2.3%
May 8, 2025Time not announced+4.1%
Feb 6, 2025Time not announced−4.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on KVUEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on KVUE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on KVUE

Technical Analysis

KVUE · as of the Oct 30 close · updated each morning
Uptrend

The stock is 3% above its 20 day and 5% above its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 60). The nearest support is the Pivot S1 at $19.01, and the nearest resistance the swing high (Jul 17) at $19.36.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 2.0%/day
Key levels
$20.1352 week high+4.2%
$19.81Pivot R1+2.6%
$19.50Pivot+1.0%
$19.36Swing high (Jul 17)+0.3%
$19.31Last close
$19.01Pivot S1−1.6%
$18.77Swing low (Jul 23)−2.8%
$18.70100 day average−3.2%
$18.6420 day average−3.5%
$18.4150 day average−4.7%
$18.19200 day average−5.8%
$14.0252 week low−27.4%
Indicators
RSI (14)59.98Middle of its rangeNeutral
MACD0.40Above its signal lineBullish
Stochastic78.3Middle of its rangeNeutral
ADX (14)34.3Trending up
Williams %R-28.1Oversold below −80, overbought above −20Neutral
CCI (20)76.6Oversold below −100, overbought above 100Neutral
Rate of change+2.1%Change over 10 sessionsBullish
ATR (14)$0.38Typical daily range, 2.0% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for KVUE

What happened before

See how KVUE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow KVUE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How KVUE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for KVUEHow many large options trades hit KVUE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

KVUE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●471 buying vs 484 selling
  • ▼Shares held by funds -3.8%
  • ●Funds holding -10
  • ▲Superinvestors: 4 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding1,0091,019−1.0%
In funds' top 102427−11.1%
Held by funds–––
New / increased88 / 383101 / 411−8.0%
Reduced / sold out393 / 91365 / 103+3.4%
Put/call ratio0.750.29+161.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KVUE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

KVUE Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$111.0M1 buy · 1 insider
Sold$747K2 sales · 2 insiders
2025-12 bought $111.0M2026-05 sold $680K2026-06 sold $67KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 10Heather HowlettCFO & CaoSale3,700$18.11$67K
May 8Matthew OrlandoGeneral CounselSale38,491$17.66$680K
Dec 12, 2025Jeffrey C SmithDirectorBuy6,377,694$17.40$111.0M
Mar 13, 2025Carlton LawsonGroup President EMEA & LASale17,100$23.03$394K
Every insider buy and sale for KVUE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See KVUE insider trades →

From SEC Form 4 filings by KVUE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

KVUE Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$0
0.0% yield
Left in program
6.6M sh
0.3% of shares
Shares outstanding, 12 months
+0.3%
More shares
Last quarter
$0
Sep 2026
Avg price paid, last quarter
—
 
S&P 500 rank by spending
—
 
Spent each quarter, last 3 yearsTop bar $120.2M
Dec 2023: $7.2M, average price $20.47Mar 2024: $91.0M, average price $19.79Jun 2024: $0Sep 2024: $23.4M, average price $21.30Dec 2024: $120.2M, average price $23.31Mar 2025: $62.8M, average price $20.94Jun 2025: $63.7M, average price $23.88Sep 2025: $70.8M, average price $20.16Dec 2025: $0Mar 2026: $0Jun 2026: $0Sep 2026: $0
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 30, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KVUE is in one of them and how their past KVUE trades turned out.

KVUE in the AI portfolios
Loading…

KVUE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KVUE in an article yet. Here's the latest on the wider market.

KVUE in the news

KVUE Congress Trades

All congress trades →
Trades, 12 months
11
Buys
5
45%
Sells
6
55%
People
4
Last filed Sep 4
Who traded KVUE · since 2023
Latest 5 filings of 27
Gilbert CisnerosSell (partial)
$1K – $15KTraded Jul 17, 2026Filed Sep 4, 2026
$1K – $15KTraded Aug 5, 2026Filed Aug 10, 2026
$1K – $15KTraded Mar 27, 2026Filed Jul 21, 2026
$1K – $15KTraded Jun 16, 2026Filed Jul 2, 2026
$1K – $15KTraded Mar 13, 2026Filed Apr 7, 2026
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CASell (partial)$1K – $15KJul 17, 2026Sep 4, 202649 d
Kevin HernR · OKSell$1K – $15KAug 5, 2026Aug 10, 20265 d
Alan ArmstrongR · OKBuy$1K – $15KMar 27, 2026Jul 21, 2026116 d
Gilbert CisnerosD · CABuy$1K – $15KJun 16, 2026Jul 2, 202616 d
Gilbert CisnerosD · CASell$1K – $15KMar 13, 2026Apr 7, 202625 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Kenvue

Kenvue is a consumer health company based in Summit, New Jersey. It makes over the counter medicines such as pain relievers and allergy treatments, along with skin and hair care, oral care, baby care, wound care and menstrual products. Well known brands include Tylenol, Listerine, Neutrogena and Johnson's. Its products are sold to consumers in many countries, and healthcare professionals help shape product development.

Headquarters
Summit, NJ